natgillin/translations-raw huggingface dataset:
Hos patienter behandlet med avelumab som monoterapi opstod immunrelateret nefritis hos 0,1 % (1/1.738) af patienterne, der fik avelumab, hvilket førte til permanent seponering af avelumab.
Immune-related nephritis and renal dysfunction In patients treated with avelumab as monotherapy, immune-related nephritis occurred in 0.1% (1/1,738) of patients receiving avelumab leading to permanent discontinuation of avelumab.
Sådan vil du få Bavencio
How you will receive Bavencio
Sådan skal du bruge Bavencio
How to use Bavencio
Meget almindelig Kvalme, diarré, forstoppelse, opkastning, abdominalsmerter Almindelig
Nausea, diarrhoea, constipation, vomiting, abdominal pain
Hos patienter behandlet med avelumab som monoterapi udviklede 1,5 % (26/1.738) af patienterne immunrelateret colitis.
In patients treated with avelumab as monotherapy, 1.5% (26/1,738) of patients developed immune-related colitis.
Der er blevet rapporteret immunrelateret pankreatitis hos patienter, der fik avelumab.
Immune-related pancreatitis has been reported in patients receiving avelumab.
Mediantiden til immunrelateret binyreinsufficiens opstod var 2,5 måneder (interval: 1 dag til 8 måneder).
The median time to onset of immune-related adrenal insufficiency was 2.5 months (range: 1 day to 8 months).
Hos patienter behandlet med avelumab i kombination med axitinib udviklede 2,7 % (13/489) af patienterne immunrelateret colitis.
In patients treated with avelumab in combination with axitinib, 2.7% (13/489) of patients developed immune-related colitis.
• Kvalme, løse afføringer, forstoppelse, opkastning
• Nausea, loose stools, constipation, vomiting
Mediantiden til tyreoideasygdomme opstod var 2,8 måneder (interval: 2 uger til 13 måneder).
The median time to onset of thyroid disorders was 2.8 months (range: 2 weeks to 13 months).
To tilfælde med dødelig udgang er blevet rapporteret hos patienter, der fik avelumab (se pkt.
Two fatal cases have been reported in patients receiving avelumab (see section 4.8).
Medianvarigheden var 6 uger (interval: 1 dag til over 14 måneder).
The median duration was 6 weeks (range: 1 day to more than 14 months).
Avelumab blev seponeret hos 0,4% (2/489) af patienterne, på grund af immunrelateret colitis.
Avelumab was discontinued in 0.4% (2/489) of patients due to immune-related colitis.
Immunerelateret binyreinsufficiens førte ikke til seponering af avelumab hos nogen patienter.
Immune-related adrenal insufficiency did not lead to discontinuation of avelumab in any patient.
• Muskelsmerter
• Muscle pain
Alle 21 patienter med immunrelateret pneumonitis blev behandlet med kortikosteroider, og 17 (81 %) af de 21 patienter blev behandlet med højdosis kortikosteroider i en mediantid på 8 dage (interval: 1 dag til 2,3 måneder).
All 21 patients with immune-related pneumonitis were treated with corticosteroids and 17 (81%) of the 21 patients were treated with high-dose corticosteroids for a median of 8 days (range: 1 day to
Alle 26 patienter med immunrelateret colitis blev behandlet med kortikosteroider og 15 (58 %) af de 26 patienter fik højdosis kortikosteroider i en mediantid på 19 dage (interval: 1 dag til 2,3 måneder).
All 26 patients with immune-related colitis were treated with corticosteroids and 15 (58%) of the 26 patients received high-dose corticosteroids for a median of 19 days (range: 1 day to 2.3 months).
• Løs afføring, kvalme, forstoppelse, opkastning
• Loose stools, nausea, constipation, vomiting
Avelumab bør afbrydes ved grad 3 eller grad 4 symptomatisk binyreinsufficiens (se pkt.
Avelumab should be withheld for Grade 3 or Grade 4 symptomatic adrenal insufficiency (see section 4.2).
Alle 16 patienter med immunrelateret hepatitis blev behandlet med kortikosteroider og 15 (94 %) af de 16 patienter fik højdosis kortikosteroider i en mediantid på 14 dage (interval: 1 dag til 2,5 måneder).
All 16 patients with immune-related hepatitis treated with corticosteroids and 15 (94%) of the 16 patients received high-dose corticosteroids for a median of 14 days (range: 1 day to 2.5 months).
• Oplysninger om, at avelumab kan forårsage alvorlige bivirkninger under og efter behandlingen,
• Information that avelumab can cause serious side effects during or after treatment, that need to be treated right away and warning message on the importance of being aware of signs and symptoms while receiving avelumab treatment
Nyrer og urinveje
Rash, pruritus
Ud af disse patienter var der 7 (0,4 %) patienter med grad 3 immunrelateret colitis.
Of these patients, there were 7 (0.4%) patients with Grade 3 immune-related colitis.
Avelumab bør tilbageholdes ved grad 2 eller grad 3 immunrelateret colitis, indtil reaktionen går væk, og skal seponeres permanent for grad 4 eller tilbagevendende grad 3 immunrelateret colitis (se pkt.
Avelumab should be withheld for Grade 2 or Grade 3 immune-related colitis until resolution, and permanently discontinued for Grade 4 or recurrent Grade 3 immune-related colitis (see section 4.2).
Avelumab blev seponeret hos 0,3 % (6/1.738) af patienterne, på grund af immunrelateret pneumonitis.
Avelumab was discontinued in 0.3% (6/1,738) of patients due to immune-related pneumonitis.
Kløende udslæt, makulopapuløst udslæt, generaliseret pruritus, dermatitis acneiform, erytem, makuløst udslæt, papulært udslæt, erytematøst udslæt, dermatitis, eksem, generaliseret udslæt
Rash pruritic, rash maculo-papular, pruritus generalized, dermatitis acneiform, erythema, rash macular, rash papular, rash erythematous, dermatitis, eczema, rash generalized
• problemer med dine hormonproducerende kirtler (skjoldbruskkirtlen, binyrerne og hypofysen),
• problems with your hormone producing glands (the thyroid, adrenal and pituitary glands) that may affect how these glands work;
Avelumab bør afbrydes ved grad 3 eller grad 4 tyreoideasygdomme (se pkt.
Avelumab should be withheld for Grade 3 or Grade 4 thyroid disorders (see section 4.2).
Andre immunrelaterede bivirkninger
Other immune-related adverse reactions
• Ledsmerter, rygsmerter, mavesmerter, muskelsmerter
• Joint pain, back pain, belly pain, muscle pain
Avelumab skal seponeres permanent ved alle grad 3 immunrelaterede bivirkninger, der vender tilbage, og ved grad 4 immunrelaterede bivirkninger (se pkt.
Avelumab should be permanently discontinued for any Grade 3 immune-related adverse reaction that recurs and for Grade 4 immune-related adverse reaction (see section 4.2).
Avelumab blev seponeret hos 0,5 % (9/1.738) af patienterne, på grund af immunrelateret hepatitis.
Avelumab was discontinued in 0.5% (9/1,738) of patients due to immune-related hepatitis.
Hos patienter behandlet med avelumab som monoterapi udviklede 1,2 % (21/1.738) af patienterne immunrelateret pneumonitis.
In patients treated with avelumab as monotherapy, 1.2% (21/1,738) of patients developed immune-related pneumonitis.
Et tilfælde med dødelig udgang er blevet rapporteret hos patienter, der fik avelumab (se pkt.
One fatal case has been reported in patients receiving avelumab (see section 4.8).
Forhøjet gamma-glutamyltransferase, forhøjet basisk phosphatase i blodet, forhøjet amylase, forhøjet lipase, forhøjet kreatinin i blodet Ikke almindelig Forhøjet alaninaminotransferase (ALAT)*, forhøjet aspartataminotransferase (ASAT)*, forhøjet kreatinphosphokinase i blodet*, forhøjede transaminer*
Alanine aminotransferase (ALT) increased*, aspartate aminotransferase (AST) increased*, blood creatine phosphokinase increased*, transaminases increased*
• Hæshed, hoste, stakåndethed
• Hoarseness, cough, shortness of breath
Hos patienter behandlet med avelumab i kombination med axitinib udviklede 6,3 % (31/489) af patienterne immunrelateret hepatitis.
In patients treated with avelumab in combination with axitinib, 6.3% (31/489) of patients developed immune-related hepatitis.
Akut nyreskade
Acute kidney injury
Formodet myokarditis
Suspected myocarditis
• Hovedpine, svimmelhed
• Headache, dizziness
Hos patienter behandlet med avelumab i kombination med axitinib udviklede 0,6 % (3/489) af patienterne immunrelateret pneumonitis.
In patients treated with avelumab in combination with axitinib, 0.6% (3/489) of patients developed immune-related pneumonitis.
Mediantiden til immunrelateret pneumonitis opstod var 2,3 måneder (interval: 2,1 uger til 14,5 måneder).
The median time to onset of immune-related hepatitis was 2.3 months (range: 2.1 weeks to 14.5 months).
Avelumab bør afbrydes ved grad 2 immunrelateret hepatitis, indtil reaktionen går væk, og skal seponeres permanent for grad 3 eller grad 4 immunrelateret hepatitis (se pkt.
Avelumab should be withheld for Grade 2 immune-related hepatitis until resolution and permanently discontinued for Grade 3 or Grade 4 immune-related hepatitis (see section 4.2).
Kontakt derimod din læge som kan
Your doctor may
Hos patienter behandlet med avelumab som monoterapi udviklede 0,9 % (16/1.738) af patienterne immunrelateret hepatitis.
In patients treated with avelumab as monotherapy, 0.9% (16/1,738) of patients developed immune-related hepatitis.
Binyreinsufficiens
Adrenal insufficiency
Hos patienter behandlet med avelumab i kombination med axitinib udviklede 1,8 % (9/489) af patienterne immunrelateret binyreinsufficiens.
In patients treated with avelumab in combination with axitinib, 1.8% (9/489) of patients developed immune-related adrenal insufficiency.
Ud af disse patienter var der 1 (0,1 %) patient med grad 3 immunrelateret binyreinsufficiens.
Of these patients, there was 1 (0.1%) patient with Grade 3 immune-related adrenal insufficiency.
Avelumab blev seponeret hos 0,2% (1/489) af patienterne, på grund af immunrelaterede tyreoideasygdomme.
Avelumab was discontinued in 0.2% (1/489) of patients due to immune-related thyroid disorders.
Pustuløst udslæt
Hepatic impairment
Der bør administreres kortikosteroider (indledende dosis på 1-2 mg/kg/dag prednison eller tilsvarende, efterfulgt af en nedtrapning af kortikosteroider) til nefritis grad ≥ 2.
Corticosteroids (initial dose of 1 to 2 mg/kg/day prednisone or equivalent followed by a corticosteroid taper) should be administered for Grade ≥ 2 nephritis.
Hypertension, hypotension Ikke almindelig Rødme
Hypertension, hypotension
• Hoste, stakåndethed
Headache, dizziness
Grad 1 infusionsrelateret reaktion
Infusion-related reactions Grade 1 infusion-related reaction
Medianalderen var 74 år (interval 41 til 93 år), 75 (65 %) var kaukasere og 72 (62 %) og 44 (38 %) havde en ECOG performancestatus på hhv. 0 og 1.
Of the 116 patients, 81 (70%) were male, the median age was 74 years (range: 41 to 93 years), 75 (65%) were Caucasian, and 72 (62%) and 44 (38%) had an ECOG performance status of 0 and 1, respectively.
Hos patienter behandlet med avelumab som monoterapi udviklede 0,5 % (8/1.738) af patienterne immunrelateret binyreinsufficiens.
In patients treated with avelumab as monotherapy, 0.5% (8/1,738) of patients developed immune-related adrenal insufficiency.
Avelumab blev seponeret hos 0,5 % (9/1.738) af patienterne, på grund af immunrelateret colitis.
Avelumab was discontinued in 0.5% (9/1,738) of patients due to immune-related colitis.
kulderystelser eller rysten, ujævnt udslæt eller hudvabler, rødmen, lavt blodtryk
bumpy rash or skin wheals, flushing, low blood pressure (dizziness, fatigue, nausea) fever,
• Forhøjet niveau af enzymer fra bugspytkirtlen i blodet
• Increased pancreatic enzymes in the blood
Afbryd
Withhold
men < 3 gange ULN, skal både Bavencio og axitinib afbrydes, indtil disse bivirkninger bedres til grad 0-1.
Treatment modifications when Bavencio is used in combination with axitinib If ALT or AST ≥ 3 times ULN but < 5 times ULN or total bilirubin ≥ 1.5 times ULN but < 3 times ULN, both Bavencio and axitinib should be withheld until these adverse reactions recover to Grades 0-1.
Meget almindelig Dysfoni, hoste, dyspnø Almindelig
Dysphonia, cough, dyspnoea
Avelumab blev seponeret hos 0,1 % (2/1.738) af patienterne, på grund af immunrelateret binyreinsufficiens.
Avelumab was discontinued in 0.1% (2/1,738) of patients due to immune-related adrenal insufficiency.
Der bør administreres kortikosteroider for immunrelateret myokarditis (indledende dosis på 1-2 mg/kg/dag prednison eller tilsvarende, efterfulgt af en nedtrapning af kortikosteroid).
Corticosteroids should be administered for immune-related myocarditis (initial dose of 1 to 2 mg/kg/day prednisone or equivalent followed by a corticosteroid taper).
Lymfopeni Ikke almindelig Trombocytopeni, eosinofili§
Thrombocytopenia, eosinophilia§
• Forhøjet sukkerniveau i blodet
• Increased glucose in the blood
Meget almindelig Træthed, kulderystelser, asteni, pyreksi Almindelig
Fatigue, chills, asthenia, pyrexia
Avelumab blev seponeret hos 0,1 % (2/1.738) af patienterne, på grund af immunrelaterede tyreoideasygdomme.
Avelumab was discontinued in 0.1% (2/1,738) of patients due to immune-related thyroid disorders.
Ud af disse patienter var der 2 (0,4 %) patienter med grad 3 immunrelateret nefritis.
Of these patients, there were 2 (0.4%) patients with Grade 3 immune-related nephritis.
Det skal du vide, før du begynder at bruge Bavencio 3.
What Bavencio is and what it is used for What you need to know before you use Bavencio How to use Bavencio
Der bør administreres kortikosteroider for immunrelateret pankreatitits (indledende dosis på 1-2 mg/kg/dag prednison eller tilsvarende, efterfulgt af en nedtrapning af kortikosteroid).
Corticosteroids should be administered for immune-related pancreatitis (initial dose of 1 to 2 mg/kg/day prednisone or equivalent followed by a corticosteroid taper).
• Øgede leverenzymer i blodet
• Increased liver enzymes in the blood
Intravenøs anvendelse efter fortynding.
Intravenous use after dilution Read the package leaflet before use.
Der bør administreres kortikosteroider ved grad ≥ 2 hændelser (indledende dosis på 1-2 mg/kg/dag prednison eller tilsvarende, efterfulgt af en nedtrapning af kortikosteroid).
Corticosteroids should be administered for Grade ≥ 2 events (initial dose of 1 to 2 mg/kg/day prednisone or equivalent, followed by a corticosteroid taper).
Ud af disse patienter var der 2 (0,4 %) patienter med grad 3 immunrelateret binyreinsufficiens.
Of these patients, there were 2 (0.4%) patients with Grade 3 immune-related adrenal insufficiency.
Ud af disse patienter var der 3 (0,2 %) patienter med grad 3 immunrelaterede tyreoideasygdomme.
Of these patients, there were 3 (0.2%) patients with Grade 3 immune-related thyroid disorders.
Meget almindelig Artralgi, rygsmerter, myalgi
Arthralgia, back pain, myalgia
Amning
Anaemia
Meget almindelig Infusionsrelateret reaktion
Infusion related reaction
Ud af disse patienter var der 2 (0,4 %) patienter med grad 3 immunrelaterede tyreoideasygdomme.
Of these patients, there were 2 (0.4%) patients with Grade 3 immune-related thyroid disorders.
Mundtørhed
Lymphopenia
Koncentrat til infusionsvæske, opløsning.
Concentrate for solution for infusion.
Dosering
Myalgia
Meget almindelig Hoste, dyspnø Almindelig
Cough, dyspnoea
Ringe
Posology
• Tarmobstruktion
Hepatobiliary disorders
Sværhedsgrad*
Uveitis*
Meget almindelig Nedsat appetit Ikke almindelig Diabetes mellitus*, type 1 diabetes mellitus*
Diabetes mellitus*, Type 1 diabetes mellitus*
• Kontakt lægen, hvis du får bivirkninger, herunder bivirkninger, som ikke er nævnt i denne indlægsseddel.
• If you get any side effects, talk to your doctor.
Særnavn Styrke
Invented name Strength
EU- nummer
EU number
Lægemiddelform
Pharmaceutical Form Route of administration Packaging
Nogle mennesker dør af denne sygdom.
Some people will die from this illness.
Derfor er den potentielle risiko for mennesker ukendt.
Therefore, the potential risk for humans is unknown.
Grunden til denne forskel er dog ukendt og kan være relateret til andre faktorer.
However the reasons for this difference are unknown and could be related to other factors.
I størstedelen af tilfældene blev der ikke observeret nogen reaktioner.
In the majority of cases, no reactions have been observed.
Derudover skal der indsendes en opdateret RMP
In addition, an updated RMP should be submitted
Risk managementplan
Risk Management Plan
Blødningsrisikoen bør tages i betragtning, når man vurderer risk-benefit for individuelle patienter.
Bleeding risk should be taken into account when considering the risk benefit for individual patients.
Hvis De er gravid, vil Deres læge kun give Dem Xigris, hvis det er nødvendigt.
If you are pregnant your doctor will only give you Xigris if necessary.
• Enhver anden tilstand, hvor lægen mener, at en signifikant blødning er sandsynlig
• Any other condition in which the physician considers significant bleeding is likely
PROWESS opfølgningsundersøgelse
PROWESS Follow-up Study
• Aktiv indre blødning
• Active internal bleeding
• Når der fremkommer nye oplysninger, der kan have indflydelse på den gældende sikkerhedsspecifikation, pharmacovigilanceplan eller risikominimerende aktiviteter
• When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities
Vær venligst opmærksom på, at De ikke kan tage Xigris selv, idet både Deres sygdom og brugen af dette lægemiddel kræver konstant overvågning af en læge.
Please remember that you cannot take Xigris by yourself because both your illness and the use of this medicine need constant medical care.
Dette medfører en sygdom, der hedder svær sepsis, og som kan gøre Dem meget syg.
This causes an illness called severe sepsis which can make you very ill.
Dette lægemiddel er godkendt under ”særlige omstændigheder”.
This medicine has been authorised under “Exceptional Circumstances”.
Der blev ikke rapporteret nogen overfølsomhedsreaktioner hos disse patienter.
No hypersensitivity reactions were reported in these patients.
• Patienter med intrakraniel patologi; neoplasme eller tegn på cerebral brok
• Patients with intracranial pathology; neoplasm or evidence of cerebral herniation
Yderligere var der ingen øget risiko for alvorlig blødning inklusive blødning i centralnervesystemet (CNS).
Additionally there was no increased risk of serious bleeding, including central nervous system (CNS) bleeding.
Under følgende forhold bør risici ved administration af Xigris afvejes mod de forventede fordele:
In the following conditions, the risks of the administration of Xigris should be weighed against the anticipated benefits:
(APACHE II score anvendes til at vurdere risikoen for dødsfald baseret på en vurdering af den akutte fysiologi og den kroniske sundhedstilstand (acute physiology and chronic health evaluation)).
(The APACHE II score is designed to assess the risk of mortality based on acute physiology and chronic health evaluation).
Muligheden for allergiske reaktioner overfor indholdsstoffer i præparatet kan dog ikke udelukkes for særligt disponerede patienter.
However, the possibility of allergic reactions to constituents of the preparation cannot be completely excluded in certain predisposed patients.
Xigris kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.
Like all medicines, Xigris can cause side effects, although not everybody gets them.
Aktiveret protein C er en afgørende koagulationsregulator.
Activated Protein C is a crucial coagulation regulator.
Overlevelsesstatus er blevet vurderet i en opfølgningsundersøgelse med overlevende fra PROWESSstudiet.
Survival status was assessed in a follow-up study of PROWESS survivors.
• Kendt blødningsdiatese undtagen akut koagulopati forbundet med sepsis
• Known bleeding diathesis except for acute coagulopathy related to sepsis
• Trombocyttal < 30.000 x 106/l, selvom trombocyttallet øges ved transfusioner
• Platelet count < 30,000 x 106/l, even if the platelet count is increased after transfusions
Drotrecogin alfa (aktiveret) [ENHANCE] N=2378
Drotrecogin alfa (activated) [ENHANCE] N=2378
I kliniske forsøg og ved postmarketing erfaring er der rapporteret om utilsigtet overdosering.
In clinical trials and in post marketing experience there have been reports of accidental overdosing.
Yderligere klinisk erfaring
Further Clinical Experience
”Som følge af usikre konklusioner af XPRESS forsøget, der undersøgte en mulig interaktion mellem Xigris og heparin, er ekstra afklaring omkring risk/benefit forholdet påkrævet.
“Further to uncertain conclusions of the XPRESS study investigating the possible interaction between Xigris and heparin, additional clarifications on the benefit/risk balance of Xigris are required.
I henhold til ”CHMP Guideline on Risk Management Systems for medicinal products for human use” skal den opdaterede RMP indsendes på samme tidspunkt som den næste periodiske sikkerhedsopdateringsrapport (PSUR).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
Hvert hætteglas svinges forsigtigt, indtil pulveret er fuldstændig opløst.
Gently swirl each vial until the powder is completely dissolved.
I tilfælde af overdosering stoppes infusionen øjeblikkeligt (se pkt.
In case of overdose, immediately stop the infusion (see section 5.2).
Undgå at udsætte opløsninger af drotrecogin alfa (aktiveret) for varme og/eller direkte sollys.
Avoid exposing drotrecogin alfa (activated) solutions to heat and/or direct sunlight.
Farmakoterapeutisk klassifikation: Antitrombotiske midler, enzymer, ATC-kode: B01A D10
Pharmacotherapeutic group: antithrombotic agents, enzymes, ATC code: B01AD10
Det betyder, at det ikke har været muligt at opnå fuldstændig dokumentation for dette lægemiddel af videnskabelige årsager.
This means that for scientific reasons it has not been possible to obtain complete information on this medicinal product.
Hvis der opstår allergiske eller anafylaktiske reaktioner, bør behandlingen straks seponeres, og relevant behandling iværksættes.
If allergic or anaphylactic reactions occur, treatment should be discontinued immediately and appropriate therapy initiated.
Patienter, som blev behandlet med Xigris, oplevede en forbedret 28 dages overlevelse sammenlignet med dem, som fik placebo.
Patients treated with Xigris experienced improved 28-day survival compared to those treated with placebo.
Efter rekonstitution anbefales det at anvende opløsningen straks.
After reconstitution, immediate use is recommended.
På grund af disse biologiske og analytiske variable bør APTT ikke anvendes til at vurdere den farmakodynamiske effekt af drotrecogin alfa (aktiveret).
Due to these biological and analytical variables, the APTT should not be used to assess the pharmacodynamic effect of drotrecogin alfa (activated).
• Kronisk svær leversygdom
• Chronic severe hepatic disease
Xigris bør ikke anvendes under graviditet, medmindre det er tvingende indiceret.
Xigris should not be used during pregnancy unless clearly necessary.
Ved procedurer, som indebærer en blødningsrisiko, skal Xigris afbrydes 2 timer før procedurens start.
For procedures with an inherent bleeding risk, discontinue Xigris for 2 hours prior to the start of the procedure.
Følgende oplysninger er kun til læger og sundhedspersonale:
The following information is intended for medical or healthcare professionals only: Instructions for use and handling
Svær sepsis er defineret som sepsis forbundet med akut organdysfunktion.
Severe sepsis is defined as sepsis associated with acute organ dysfunction.
Indehaveren af markedsføringstilladelsen skal fortsætte med at indsende årlige PSUR'er.
The Marketing Authorisation Holder will continue to submit yearly PSURs.
Excessiv aktivering af koagulationen i det mikrocirkulatoriske karsystem spiller en væsentlig rolle i patofysiologien af svær sepsis.
Excessive coagulation activation in the microcirculatory bed plays a significant part in the pathophysiology of severe sepsis.
Derudover er aktiveret protein C en vigtig modulator i det systemiske respons på infektion og har antitrombotiske og profibrinolytiske egenskaber.
Furthermore, Activated Protein C is an important modulator of the systemic response to infection and has antithrombotic and profibrinolytic properties.
Der var ingen statistisk forskel i hyppigheden af VT mellem forsøgsarmene.
There was no statistical difference in the rates of VTE between study arms.
Denne væske løber fra en pose gennem en slange og ind i en af Deres blodårer i en periode på 96 timer.
This liquid is then passed from a bag through a tube into one of your veins for a period of 96 hours.